ImmunityBio Jumps Again as Traders Look to Anktiva News
ImmunityBio filed a Form 144 on June 4 to sell 268,033 common shares valued at about $2.95 million. Shares rose 3.0% to $7.395 in afternoon trading, with volume near 5.8 million. The FDA set a January 6, 2027, decision date for an expanded Anktiva bladder-cancer label. First-quarter net product revenue reached $44.2 million, up 168% from a year ago.